| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Rare Diseases |
Recent Updates
Recently added Catalysts
Monopar Therapeutics Inc.$109.24
-0.88 (-0.8%)
D 31Pipeline Score Overvalued Biotech · Clinical
Market Cap
422.84 M
EPS
-2.07
P/E Ratio
-
Value Trade
4.34 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
3.49 M
Operating CF
-3.47 M
Total Assets
137.98 M
Total Liabilities
2.59 M
Equity
135.39 M
D/E Ratio
12,345
5.8 %
Week
18.76 %
1 Month
15.63 %
3 Month
-23.53 %
6 Month
129.53 %
5 Year
51.19 %
All Time
Cash Data
Cash Position
104.91 M
Monthly Burn
1.16 M
Runway
88.1 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
26.80 K
52 Week Range
28.40 - 105
% held by Insiders
37.85 %
% held by Institutions
81.1 %
Enterprise Value
285.48 M
Total Shares
6.70 M
Short %
28.04 %
Float Shares
4.85 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Monopar Therapeutics Inc.
284Total events
3Upcoming
47Tier-1 (high impact)
2019 – 2026Coverage
Upcoming catalysts 2
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
●Rolling Submission InitiatedALXN-1840FiledRegulatory Filing
Subscribe to view catalyst details
TBD
●Management ChangeCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | ALXN1840 (tiomolibdate choline, TMC) | NDA Submission | NDA | — | – | – | – |
2026-06-30 | ALXN1840 (tiomolibdate choline, TMC) | NDA Submission | NDA | — | – | – | – |
2026-06-30 | ALXN1840 (tiomolibdate choline, TMC) | NDA Submission | NDA | — | – | – | – |
Drug Pipeline Intelligence
D31
Pipeline Score $76M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 40%
Micro Cap (rank 549 of 913)
Percentile RankMonopar Therapeutics Inc. faces pipeline headwinds (31/100), with $380M risk-adjusted pipeline value, led by MNPR-101-PCTA-177Lu in Solid Tumor, Adult (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MNPR-101-PCTA-177Lu Small molecule | Solid Tumor, Adult | Phase 1 | NCT06617169 | 5% | $190M | RECRUITING | 12 | STALLED | D (26) | Jan 1, 2027 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ALXN1840 Fast TrackOrphanRare Pediatric | Wilson disease | Phase 3 | 2026-06-26 | In the Phase 3 FoCus trial of ALXN1840 for Wilson disease, patients showed significant neurologic improvement (p=0.006) and greater global clinical improvement at Week 48 (p<0.001) compared to standard of care, with a total of 207 participants. Read More | Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease Read More | |
ALXN1840 Fast TrackOrphanRare Pediatric | Wilson disease | Phase 3 | 2026-06-26 | In the Phase 3 FoCus trial of ALXN1840 for Wilson disease, patients showed significant neurologic improvement (p=0.006) and greater global clinical improvement at Week 48 (p<0.001) compared to standard of care, with a total of 207 participants. Read More | Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease Read More | |
ALXN1840 Fast TrackOrphanRare Pediatric | Wilson disease | Phase 3 | 2026-06-26 | In the Phase 3 FoCus trial of ALXN1840 for Wilson disease, patients showed significant neurologic improvement (p=0.006) and greater global clinical improvement at Week 48 (p<0.001) compared to standard of care, with a total of 207 participants. Read More | Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MNPR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MNPR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MNPRMonopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
Monopar Therapeutics has begun the rolling submission of a New Drug Application (NDA) for ALXN1840, a novel treatment for Wilson disease. This marks a significant milestone as it may lead to the first new therapy for the condition in decades. The FDA has granted several designations to ALXN1840, enhancing its potential for approval. However, uncertainties regarding regulatory acceptance and market competition remain.
Read more →MNPRMonopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
Monopar Therapeutics has bolstered its commercial leadership team in anticipation of launching its first product, ALXN1840, pending FDA approval. Nicole Sweeny has joined the Board of Directors, while Sharon Funk and Daniel Olmstead have been appointed to senior roles. The company aims to submit an NDA for ALXN1840 in mid-2026, targeting Wilson disease treatment.
Read more →MNPRMonopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
Monopar Therapeutics announced that the FDA has granted Rare Pediatric Disease designation to its candidate ALXN1840 for Wilson disease. This designation could allow the company to obtain a pediatric Priority Review Voucher upon NDA approval, expediting the review process. ALXN1840 has demonstrated significant efficacy in clinical trials, showing improved copper balance in patients. The company emphasizes the urgent need for new treatment options for this serious condition.
Read more →MNPR▲ +7.8%on this newsshared move
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Monopar Therapeutics presented new analyses from the Phase 3 FoCus trial of ALXN1840 at EAN 2026. The data demonstrated significant neurologic and global clinical improvements in Wilson disease patients compared to standard care. The findings support the company's upcoming New Drug Application submission to the FDA for ALXN1840, which has shown a favorable safety profile in previous studies.
Read more →MNPRMonopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
Monopar Therapeutics presented promising Phase 2 data for ALXN1840 at EASL 2026, showing stabilization of liver disease and improvements in neurologic symptoms in Wilson disease patients. The study involved 29 treatment-experienced patients and highlighted significant clinical outcomes, including quality of life enhancements. The results underscore ALXN1840's potential to address unmet medical needs in this patient population.
Read more →MNPRMonopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
Monopar Therapeutics announced the publication of a Phase 2 study demonstrating that ALXN1840 significantly improves copper balance in patients with Wilson disease. The study showed a rapid and sustained improvement in daily copper balance, attributed to increased fecal copper excretion. ALXN1840 was well tolerated, indicating its potential as a new treatment option for this rare genetic condition.
Read more →MNPRMonopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Monopar Therapeutics reported its first quarter 2026 financial results, highlighting a net loss of $3.9 million. The company is on track to submit a New Drug Application for ALXN1840 for Wilson disease by mid-2026, following positive results from the Phase 3 FoCus trial. Monopar's cash reserves are projected to sustain operations through 2027, despite rising R&D expenses.
Read more →MNPRMonopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Therapeutics presented Phase 3 data for ALXN1840 at the AAN Annual Meeting 2026, demonstrating significant neurologic benefits compared to standard of care in Wilson disease patients. The findings indicate that ALXN1840 not only improves clinical outcomes but also reduces the likelihood of neurologic deterioration. The company plans to submit a New Drug Application to the FDA in mid-2026.
Read more →MNPRMonopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Monopar Therapeutics announced its fourth quarter and full-year 2025 financial results, highlighting a productive year marked by advancements in the development of ALXN1840 for Wilson disease. The company plans to submit a New Drug Application for ALXN1840 in mid-2026. Despite a reduced net loss, the company faces ongoing regulatory uncertainties and increased expenses.
Read more →MNPRMonopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Monopar Therapeutics has appointed Susan Rodriguez as Chief Commercial and Strategy Officer to lead its commercial strategy. This role comes as the company prepares to submit a New Drug Application for ALXN1840, a therapy for Wilson disease. Rodriguez brings over 30 years of experience in biopharmaceuticals, having previously held leadership positions at Avadel Pharmaceuticals and Ardelyx.
Read more →MNPR▲ +5.4%on this news
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
Monopar Therapeutics reported its third quarter 2025 financial results, highlighting significant developments in its clinical programs. The company showcased promising data for ALXN1840 in treating Wilson disease and received FDA clearance for MNPR-101-Lu. Despite a net loss increase, Monopar raised $126.9 million through a public offering to support ongoing operations and future drug applications.
Read more →MNPRMonopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
Monopar Therapeutics presented promising data on ALXN1840, a treatment for Wilson disease, at the AASLD 2025 conference. The Phase 2 study showed a rapid and sustained improvement in copper balance among patients, primarily through increased fecal copper excretion. The findings suggest that ALXN1840 could be an effective therapy for managing Wilson disease.
Read more →MNPR▼ -5.1%on this news· ran to -19% by day 3
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
Monopar Therapeutics announced that its abstract on the Phase 2 ALXN1840-WD-204 study has been accepted for oral presentation at the AASLD – The Liver Meeting® 2025. The event will take place in Washington, D.C., from November 7-11, 2025. The presentation materials will be available on the company's website shortly after the event.
Read more →MNPR▲ +7.9%on this news
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Monopar Therapeutics Inc. has announced the pricing of a $135 million underwritten offering of common stock and pre-funded warrants. The offering includes 1,034,433 shares priced at $67.67 each, with expected net proceeds of approximately $100 million. Monopar plans to utilize the funds for general corporate purposes, including R&D and a stock repurchase from Tactic Pharma.
Read more →MNPR▲ +7.9%on this newsshared move
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
Monopar Therapeutics announced the publication of a peer-reviewed Letter to the Editor in the Journal of Hepatology, highlighting that ALXN1840 significantly improves copper balance in Wilson disease patients. The analysis corrected previous methodological limitations from a Phase 2 study, demonstrating enhanced copper excretion. This publication reinforces the therapeutic potential of ALXN1840 for treating Wilson disease.
Read more →MNPR▲ +10.7%on this news· ran to +35% by day 3
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
Monopar Therapeutics announced the presentation of new long-term data on ALXN1840 for Wilson disease at the 150th ANA Annual Meeting. The findings indicate significant neurological benefits and safety for patients, reinforcing the therapy's potential. The data, pooled from multiple clinical trials, highlights the treatment's efficacy over an average duration of 2.6 years.
Read more →MNPR▲ +6.7%on this news· ran to +22% by day 3
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
Monopar Therapeutics announced that its abstract on ALXN1840 for Wilson disease has been accepted for both oral and poster presentations at the upcoming American Neurological Association Annual Meeting. The abstract, which discusses long-term neurological benefits, has received the prestigious designation of Abstract of Distinction. Presentations will be available online in mid-September 2025.
Read more →MNPR▲ +14.6%on this news
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
Monopar Therapeutics Inc. reported its financial results for Q2 2025, highlighting the successful transfer of the IND application for ALXN1840 from Alexion Pharmaceuticals. The company is preparing to submit a New Drug Application to the FDA in early 2026. Their MNPR-101 clinical trials are active in Australia and the U.S. The company reported a net loss of $2.5 million for the quarter, with increased expenses in both R&D and G&A sectors but maintains sufficient funding to continue operations through 2026.
Read more →MNPRMonopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
Monopar Therapeutics has announced the authorization of an Expanded Access Program (EAP) for its investigational agents MNPR-101-Zr and MNPR-101-Lu, aimed at treating advanced solid tumors. The EAP, which is now open for enrollment at EDNOC in Houston, Texas, allows patients access to these therapies under the supervision of Dr. Ebrahim S. Delpassand. This initiative follows the initiation of Phase 1 clinical trials in Australia, marking a significant step in Monopar's radiopharmaceutical pipeline.
Read more →MNPR▲ +7%on this news· ran to +24% by day 3
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Monopar Therapeutics has announced its inclusion in the Russell 3000® and Russell 2000® Indexes, effective June 27, 2025. This milestone highlights the company's growth and the recognition of its late-stage drug candidate for Wilson disease. The Russell Indexes are widely used benchmarks for investment strategies, indicating increased visibility for Monopar.
Read more →MNPRMonopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
Monopar Therapeutics announced its first quarter 2025 financial results, highlighting progress on its ALXN1840 treatment for Wilson disease. Recent data presented at the EASL International Liver Congress demonstrated sustained efficacy and a favorable safety profile for ALXN1840. The company also provided updates on its MNPR-101 programs for advanced cancers and indicated that its financial position is solid enough to support operations until December 2026, including plans to file a New Drug Application with the FDA. Overall, the company appears to be on a positive trajectory concerning its clinical programs and financial sustainability.
Read more →MNPRMonopar Presents ALXN1840 Late-Breaker Data at EASL 2025
Monopar Therapeutics presented new data on its drug candidate ALXN1840 for Wilson disease at the EASL International Liver Congress 2025. The late-breaker presentation highlighted significant long-term efficacy, showing sustained improvements in patient-reported outcomes and clinician assessments. Additionally, ALXN1840 demonstrated increased copper mobilization and a favorable safety profile, with fewer than 5% of patients experiencing serious adverse events. Dr. Karl Weiss emphasized that the results suggest ALXN1840 could meaningfully improve the daily lives of patients with Wilson disease.
Read more →MNPRMonopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
Monopar Therapeutics Inc. announced that data on its drug candidate ALXN1840 for Wilson disease has been accepted for a late-breaker poster presentation at the EASL International Liver Congress 2025. This prestigious event is set to be held in Amsterdam from May 7 to May 10, 2025. The late-breaker presentation is significant, as it highlights recent advancements and potentially impactful findings in the field. The presentation will be delivered by Dr. Karl Heinz Weiss and will focus on the sustained long-term clinical improvement of Wilson disease patients treated with tiomolybdate choline.
Read more →MNPR▼ -9.7%on this news
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
Monopar Therapeutics Inc. announced its fourth quarter and full-year 2024 financial results, citing a productive year characterized by several key developments, including the in-licensing of ALXN1840 for Wilson disease and the initiation of Phase 1 clinical trials for MNPR-101. The company raised significant funds, exceeding $55 million, which will aid in advancing their clinical programs. Nevertheless, Monopar reported increased net losses and soaring R&D expenses, raising concerns about the sustainability of its financial health. The planned NDA submission for ALXN1840 in early 2026 underscores Monopar's forward-looking strategy despite current challenges.
Read more →MNPR▲ +8.5%on this news
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
Monopar Therapeutics Inc. has announced the pricing of a $40 million public offering of its common stock, involving the sale of 798,655 shares at $23.79 each and a private placement of pre-funded warrants. The gross proceeds will be directed towards general corporate uses, including research, development expenditures, and working capital. The offering is set to close around December 23, 2024, pending customary conditions. This initiative reflects the company's ongoing efforts to fund its promising treatments for unmet medical needs.
Read more →MNPR▼ -14.8%on this news
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
Monopar Therapeutics announced that it has successfully dosed its first patient with MNPR-101-Lu, a novel therapeutic radiopharmaceutical targeting uPAR, which is involved in aggressive cancers. This treatment was administered under a compassionate use protocol, and the patient was well-tolerated without serious adverse reactions. The company is also enrolling participants in two Phase 1 clinical studies in Australia, focusing on advanced solid tumors and imaging agents. The dosing marks a significant milestone in potential cancer therapy advancements.
Read more →MNPR▲ +5.3%on this newsshared move
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
Monopar Therapeutics Inc. will participate in the 36th Annual Piper Sandler Healthcare Conference, featuring a fireside chat by CEO Chandler Robinson. Scheduled for December 5, 2024, the event will take place at the Lotte New York Palace. Monopar is recognized for its development of treatments for Wilson disease and advanced cancers, which could attract investor interest.
Read more →MNPR▲ +7.3%on this news· ran to +22% by day 3
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
Monopar Therapeutics reported its financial results for Q3 2024, highlighting significant advancements in its clinical pipeline. The company secured an exclusive license for ALXN-1840, a late-stage drug candidate for Wilson disease, and commenced two clinical trials for novel radiopharmaceutical therapies targeting advanced solid cancers. Financially, Monopar generated $17.7 million from a public offering, providing it sufficient funds to sustain operations into the first half of 2026. However, the report also noted a net loss, albeit improved compared to the previous year.
Read more →MNPR▼ -9.5%on this news
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
Monopar Therapeutics Inc. has successfully closed a public offering of common stock, raising approximately $19.2 million at a price of $16.25 per share. The offering was facilitated by Janus Henderson Investors, RA Capital Management, and other notable investors. Proceeds will be allocated for general corporate purposes, including research and development, clinical trials, and working capital. The move underscores the company's focus on expanding its clinical-stage biopharmaceuticals and fulfilling unmet medical needs.
Read more →MNPR▼ -9.1%on this newsshared move
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
Monopar Therapeutics Inc. has announced the pricing of its public offering of common stock at $16.25 per share, totaling approximately $19.2 million in gross proceeds. The offering is expected to close on October 30, 2024, pending customary closing conditions. The funds raised are intended for general corporate purposes, including research and development, clinical trial expenditures, and working capital. Notable investors such as Janus Henderson Investors and RA Capital Management participated in the offering.
Read more →MNPR▲ +5.3%on this newsshared move
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
Monopar Therapeutics Inc. has announced its intention to conduct a public offering of common stock, which will be sold entirely by the company. The proceeds from this offering are intended for general corporate purposes including R&D and clinical trials. The offering is subject to market conditions, and specifics regarding size and terms are yet to be finalized. Rodman & Renshaw LLC has been appointed as the placement agent for this offering. The company's registration statement on Form S-3 has been filed with the SEC, and more details will follow in a prospectus supplement.
Read more →MNPR▲ +605.4%on this newsshared move
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
Monopar Therapeutics has entered into an exclusive licensing agreement with Alexion, AstraZeneca Rare Disease to acquire ALXN-1840, a drug candidate for Wilson disease. This candidate previously completed a pivotal Phase 3 trial that met its primary endpoint. Monopar will take on responsibilities for the global development and commercialization of ALXN-1840, addressing significant unmet medical needs for patients with Wilson disease. However, potential risks exist due to the termination of the program by Alexion and the uncertainties surrounding regulatory approval.
Read more →MNPRMonopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
Monopar Therapeutics Inc. presented encouraging clinical and preclinical data on its MNPR-101 radiopharmaceutical program at the EANM 2024 Annual Congress. The data show a favorable organ safety profile and effective tumor uptake with low off-target binding. The presentation was recognized as a 'Top-Rated Oral Presentation,' underlining the potential of uPAR-targeted treatments for solid tumors. However, the company noted potential risks and uncertainties regarding future trial results and patient enrollment.
Read more →MNPRMonopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
Monopar Therapeutics, a clinical-stage radiopharma company, has announced the filing of a provisional patent for new therapeutic radiopharmaceuticals incorporating a family of linkers. These linkers are designed to improve stability and biodistribution of their treatment options, including their uPAR targeting antibody MNPR-101. The innovation opens possibilities for targeting established cancer objectives and may attract industry collaborations. The company emphasizes its commitment to advancing the radiopharma sector through these developments.
Read more →MNPR▲ +10.2%on this news
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
Monopar Therapeutics Inc. has announced the activation and patient recruitment for its Phase 1a clinical trial of the novel radiopharmaceutical MNPR-101-Lu, aimed at treating advanced cancers. This open-label trial will investigate MNPR-101-Lu's efficacy in patients with solid tumors and is linked to the ongoing MNPR-101-Zr imaging trial. The company is optimistic about the treatment's potential, highlighting previous encouraging clinical data. However, risks include patient recruitment challenges and potential issues with the efficacy or safety of the therapies.
Read more →MNPR▲ +64.6%on this news
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
Monopar Therapeutics Inc. has reported encouraging early results from its MNPR-101-Zr Phase 1 clinical trial, confirming the compound's ability to effectively target tumors in humans. The trial showcased the specific uptake of MNPR-101-Zr in metastatic tumors, aligning with previous imaging results. The company is set to launch further trials, including an MNPR-101-Lu Phase 1 therapeutic study later this year, which highlights their commitment to advancing cancer treatments.
Read more →MNPRMonopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Monopar Therapeutics Inc. will present at the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9, 2024. CEO Chandler D. Robinson will be presenting, with the webcast starting at 7:00 a.m. ET. The conference will also feature in-person one-on-one meetings from September 9 to 11, 2024, at the Lotte New York Palace. Monopar focuses on developing innovative treatments for cancer patients, including multiple projects in various stages of development.
Read more →MNPR▼ -8.4%on this news
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
Monopar Therapeutics Inc. has announced its compliance with the Nasdaq minimum bid price requirement, following a period where its common stock price consistently closed above $1.00 across 10 trading sessions. This compliance with Nasdaq Listing Rule 5550(a)(2) secures their continued listing on the exchange. The company is focused on developing innovative cancer treatments and has several promising products in various stages of development.
Read more →MNPRMonopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
Monopar Therapeutics Inc. announced the approval from the Human Research Ethics Committee in Australia to initiate a Phase 1 clinical trial for MNPR-101-Lu, a novel radiopharmaceutical targeting uPAR-positive tumors. The drug has shown promising results in preclinical models, specifically in pancreatic cancer, demonstrating durable antitumor effects. This trial is expected to enroll patients with advanced solid cancers, following an ongoing imaging and dosimetry trial. Monopar's CEO expressed optimism about the potential benefits of MNPR-101-Lu for patients with aggressive cancers.
Read more →MNPR▼ -5.8%on this news
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
Monopar Therapeutics Inc. has successfully dosed the first patient in its Phase 1 clinical trial for the radiopharmaceutical MNPR-101-Zr, aimed at cancer imaging. Initial data indicate that the treatment was well-tolerated with no serious adverse reactions and a favorable safety profile. Biodistribution studies show low radiation exposure to healthy organs, enhancing confidence in the trial's prospective results. The study seeks to include patients with cancers expressing high uPAR levels to better understand the drug's efficacy.
Read more →MNPR▼ -19.6%on this newsshared move
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
Monopar Therapeutics has reported its second quarter 2024 financial results, announcing the initiation of a first-in-human Phase 1 clinical trial for its MNPR-101-Zr radiopharmaceutical. The company remains on track to start a therapeutic trial for MNPR-101-RIT in Q4 2024, supported by promising preclinical data. A collaboration with NorthStar Medical Radioisotopes has also been established, enhancing its supply chain. However, the firm predicts it will need to secure additional funding within the next year to maintain operations and continued development.
Read more →MNPR▼ -19.6%on this newsshared move
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
Monopar Therapeutics Inc. has announced a 1-for-5 reverse stock split of its common stock, effective August 12, 2024. This decision was approved by stockholders at the Annual Meeting on August 5, 2024. The move aims to regain compliance with Nasdaq's listing rules, as the number of outstanding shares will decrease significantly from approximately 17.6 million to about 3.5 million. The reverse split will not affect the number of authorized shares or their par value.
Read more →MNPRMonopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
Monopar Therapeutics has announced the enrollment of the first patient in its Phase 1 clinical trial for MNPR-101-Zr, a novel radiopharmaceutical targeting advanced cancers. The trial, led by Professor Rodney Hicks, aims to evaluate the safety and dosimetry of this innovative imaging agent. MNPR-101-Zr combines antibody targeting with zirconium-89 radioisotope to improve cancer imaging. While early preclinical results are encouraging, there are inherent risks associated with the trial and potential adverse effects.
Read more →MNPRMonopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
Monopar Therapeutics announced that its abstract on the anti-uPAR antibody MNPR-101-RIT has been accepted as a top-rated oral presentation for the EANM 2024 Congress. This program targets cancers expressing the urokinase plasminogen activator receptor, showing promising preclinical data for treating solid tumors. Additionally, the company has initiated a Phase 1 clinical trial for its MNPR-101-Zr imaging agent in advanced cancer patients. While the acceptance at EANM highlights the project's merit, it also comes with inherent risks and uncertainties typical in clinical development.
Read more →MNPR▲ +5.2%on this news· ran to +21% by day 3
Monopar and NorthStar Amend & Extend Collaboration
Monopar Therapeutics and NorthStar Medical Radioisotopes have amended and extended their collaboration, establishing a long-term supply agreement for actinium-225. Monopar gains full ownership of intellectual property related to its MNPR-101 radiopharma platform, enhancing its developmental prospects. The partnership aims to leverage NorthStar's capability as a commercial-scale producer of actinium-225 to support Monopar's future commercial programs and bolster treatment options for aggressive cancers.
Read more →MNPRMonopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
Monopar Therapeutics Inc. presented data on its lead radiopharmaceutical program, MNPR-101-Zr, at the 2024 SNMMI Annual Meeting. The data highlights robust tumor uptake in various cancer models and supports the potential of the urokinase plasminogen activator receptor (uPAR) as a target. The company recently commenced a Phase 1 clinical trial for MNPR-101-Zr in advanced cancer patients. Such advancements position Monopar at the forefront of radiopharmaceutical development for cancer treatment.
Read more →MNPRMonopar Announces CFO Succession
Monopar Therapeutics announced the retirement of Chief Financial Officer Kim R. Tsuchimoto after 35 years. Karthik Radhakrishnan, who has over 20 years of financial experience, will take over the role beginning July 1, 2024. The leadership transition has been in preparation for more than six months, and Radhakrishnan expressed enthusiasm for Monopar's innovative cancer treatments.
Read more →MNPR▼ -5.2%on this news
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
Monopar Therapeutics has reported its first-quarter 2024 financial results while emphasizing its strategic focus on its radiopharmaceutical pipeline. The company has initiated a first-in-human Phase 1 clinical trial for MNPR-101-Zr and is planning to launch another trial, MNPR-101-RIT, by early next year. Despite promising developments, Monopar highlighted the need for additional funding to support ongoing and future programs, and a net loss was reported for the quarter. The company remains optimistic about its advancements in cancer treatment through innovative radiopharma solutions.
Read more →MNPRMonopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Monopar Therapeutics Inc. announced that its abstract regarding the preclinical data for its radiopharmaceutical program MNPR-101-Zr has been accepted for presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting. The event is set to take place from June 8 to June 11, 2024, in Toronto, Canada. SNMMI is renowned as a leading forum for education and research in the radiopharmaceutical industry, highlighting advancements and innovations.
Read more →MNPRMonopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
Monopar Therapeutics Inc. has filed a provisional patent application to protect advancements made in its MNPR-101 radiopharmaceutical program. The patent, covering the MNPR-101-Zr construct and its variations, aims to enhance the construct's clinical profile. Additionally, Monopar has commenced a Phase 1 dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients, intending to develop novel therapies targeting hard-to-treat cancers. The filing is positioned as a strategic move to bolster Monopar's intellectual property portfolio further.
Read more →MNPR▲ +8.4%on this news· ran to +30% by day 1
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
Monopar Therapeutics has commenced a Phase 1 clinical trial for its radiopharmaceutical imaging agent MNPR-101-Zr, aimed at patients with advanced cancers. The trial, which is open for patient recruitment at the Melbourne Theranostic Innovation Centre, will evaluate the safety and dosimetry of the agent, which has shown promising preclinical efficacy. If successful, Monopar plans to expand further studies involving therapeutic radioisotopes. The trial is being conducted under the guidance of a noted expert in the field, enhancing the potential for successful outcomes.
Read more →MNPR▼ -7.6%on this news
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
Monopar Therapeutics Inc. reported its financial results for the fourth quarter and full year of 2023, highlighting significant progress in its MNPR-101 and Camsirubicin clinical programs. The company is set to commence a Phase 1 dosimetry trial for MNPR-101 with Human Research Ethics Committee clearance. Positive preclinical data support the efficacy of MNPR-101 in eliminating tumors in various cancer models. Financially, Monopar reported a reduced net loss compared to the previous year and anticipates sufficient funding to continue its operations until at least June 2025.
Read more →MNPR▲ +7.1%on this news· ran to -18% by day 3
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
Monopar Therapeutics Inc. announced positive preclinical imaging data for its MNPR-101 radiopharma program, highlighting significant tumor uptake of a therapeutic radioisotope. This data supports the efficacy of MNPR-101 in targeting uPAR-positive tumors. The results align with previously released biodistribution and efficacy data, adding confidence in Monopar's ongoing clinical strategies. The company also received clearance to begin a Phase 1 trial in Australia, advancing its efforts in the oncology space.
Read more →MNPR▼ -10.4%on this news· ran to -34% by day 3
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
Monopar Therapeutics has appointed Professor Rodney Hicks as the lead investigator for the MNPR-101-Zr Phase 1 dosimetry clinical trial. The trial will focus on advanced cancer patients at the Melbourne Theranostic Innovation Centre using cutting-edge imaging technology. This initiative aims to address high unmet medical needs in cancers such as pancreatic and triple-negative breast cancer. However, there remain several risks associated with the trial, including the potential for unexpected adverse effects and regulatory delays.
Read more →MNPR▲ +96.5%on this news· ran to +128% by day 1shared move
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
Monopar Therapeutics has announced promising preclinical results for its MNPR-101 radiopharmaceutical program, which targets advanced cancers expressing the uPAR receptor. The data demonstrate significant tumor uptake and anti-tumor benefits in animal models. The company has also obtained clearance to commence a Phase 1 clinical trial in Australia. These developments highlight the potential of MNPR-101 as an innovative treatment option for patients with difficult-to-treat cancers.
Read more →MNPR▲ +95.3%on this newsshared move
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
Monopar Therapeutics announced clearance from the Human Research Ethics Committee in Australia to begin a Phase 1 dosimetry trial for its radiopharmaceutical MNPR-101-Zr. This trial will target patients with advanced cancers and will employ positron emission tomography (PET) for assessment. The drug is a novel version of MNPR-101, which demonstrated selective tumor uptake in preclinical studies. The company is enthusiastic about this milestone, citing potential benefits for cancer treatment in future phases.
Read more →MNPRMonopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
Monopar Therapeutics reported its third-quarter financial results and significant progress in its cancer treatment programs. The company is advancing its MNPR-101 radiopharmaceutical towards a first-in-human clinical study, expected to start by December 2023. Their Phase 1b trial of camsirubicin has shown promising tumor reductions in patients with advanced soft tissue sarcoma. Additionally, preclinical results for MNPR-202 suggest its potential as a non-cardiotoxic alternative to doxorubicin. However, the company noted the need for additional funding and highlighted a case of potential cardiotoxicity in one of the trial participants.
Read more →MNPR▲ +27.9%on this news
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Monopar Therapeutics Inc. presented promising data regarding its Phase 1b clinical trial of camsirubicin for advanced soft tissue sarcoma at the 2023 CTOS Annual Meeting. The results showed that 9 out of 14 patients had stable disease, with some experiencing significant tumor size reduction. The trial has not reported any dose-limiting toxicities to date, although one patient has shown a decline in left ventricular ejection fraction. The findings suggest potential benefits of camsirubicin over traditional treatments like doxorubicin, particularly regarding cardiac safety.
Read more →MNPR▼ -6%on this news
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
Monopar Therapeutics Inc. will present at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023. Andrew J. Cittadine, the Chief Operating Officer, will showcase the company's efforts and pipeline in cancer treatment. Monopar is focused on delivering innovative therapies, including camsirubicin and various antibody treatments, aimed at advanced cancers. The event will be held at The Yale Club in New York City.
Read more →MNPRMonopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Monopar Therapeutics Inc. will present at the H.C. Wainwright 25th Annual Global Investment Conference. CEO Chandler D. Robinson is scheduled to begin the company’s webcast presentation on September 11, 2023, at 7:00 a.m. ET. The event includes opportunities for in-person one-on-one meetings from September 11 to 13, 2023, at Lotte New York Palace, NY. Monopar is focused on developing cancer treatments with a pipeline including drugs in various stages of clinical development.
Read more →MNPRMonopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
Monopar Therapeutics reported its second-quarter 2023 financial results, highlighting advances in its Camsirubicin Phase 1b trial where patients have shown significant tumor size reductions. The company is also progressing its MNPR-101 radiopharma program toward first-in-human studies, potentially by the end of this year. Financially, Monopar has sufficient funds to sustain operations through September 2024 but anticipates the need for additional capital in the next 12 months to support ongoing research and development.
Read more →MNPR▲ +15.2%on this newsshared move
Monopar Provides Encouraging Camsirubicin Clinical Data Update
Monopar Therapeutics provided a promising update on its Phase 1b clinical trial of camsirubicin, a treatment for advanced soft tissue sarcoma. Initial results show tumor size reductions of 18% and 20% in two patients. The trial supports the hypothesis that camsirubicin may retain anti-cancer activity while reducing the risk of heart damage compared to doxorubicin. Furthermore, safety data reveals no significant drug-related cardiotoxicity, with a majority of patients experiencing minimal side effects.
Read more →MNPRMonopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
Monopar Therapeutics has announced a collaboration with the Cancer Science Institute of Singapore to evaluate MNPR-101, a radiopharmaceutical targeting aggressive cancers. This partnership focuses on assessing uPAR expression in patients with advanced soft tissue sarcoma to personalize treatment approaches. Principal Investigator Dr. Anand Jeyasekharan will guide the study, which holds potential for merging precision medicine with advanced oncology therapies. However, there are inherent uncertainties regarding the outcomes of the studies and the commercialization of MNPR-101.
Read more →MNPRMonopar to Participate in the Radiopharma Forum by the Lake 2023
Monopar Therapeutics Inc. announced its participation in the Radiopharma Forum by the Lake on June 26, 2023, where CEO Chandler Robinson will discuss the company's advancements. The company aims to showcase its lead radiopharmaceutical program targeting uPAR and a patented linker that binds to actinium-225 efficiently. The properties of actinium-225 position it as a promising therapeutic isotope for cancer treatments. Monopar's ongoing efforts in developing innovative cancer therapies are underscored through its participation in this leading forum.
Read more →MNPRMonopar to Participate in the Maxim Group’s Healthcare Virtual Conference
Monopar Therapeutics Inc. will participate in the Maxim Group’s Healthcare Virtual Conference on June 20, 2023, featuring CEO Chandler Robinson in a fireside chat. The company emphasizes its dedication to developing cancer treatments, with a pipeline that includes camsirubicin for advanced soft tissue sarcoma and other therapeutics for various cancers. This event reflects Monopar's strategy to engage with investors and raise awareness about its ongoing efforts in the biopharmaceutical field.
Read more →MNPR▲ +7.4%on this news
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update Patient in 520 mg/m 2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients
Monopar Therapeutics announced promising updates from its Phase 1b clinical trial for camsirubicin, designed for patients with advanced soft tissue sarcoma. In the trial's 520 mg/m2 cohort, one patient experienced significant tumor shrinkage allowing for subsequent surgical resection, while all participants achieved stable disease. The trial has shown improvement in median progression-free survival compared to earlier studies, and there have been no observed drug-related cardiotoxicity effects. The outcome supports the hypothesis that camsirubicin could provide a safer alternative to traditional treatments.
Read more →MNPR▼ -6.6%on this news
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments Camsirubicin Phase 1b Dose-Escalation Trial Enrolling 5th Dose-Level Cohort (650 mg/m 2 ) MNPR-101 RIT Shows Promising Imaging and
Monopar Therapeutics reported its first quarter 2023 financial results, highlighting advancements in its clinical trials, particularly the camsirubicin Phase 1b trial for advanced soft tissue sarcoma, which is currently enrolling its fifth dose-level cohort. Encouraging results indicate improved patient outcomes and low incidences of side effects compared to conventional treatments. Furthermore, promising preclinical studies on MNPR-101 and MNPR-202 signal potential breakthroughs in cancer therapies. However, the company discontinued its Validive trial due to insufficient efficacy results and anticipates the need for additional funding in the near future.
Read more →MNPR▼ -51.3%on this news
Monopar to Present at the Jefferies Radiopharma Innovation Summit
Monopar Therapeutics Inc. will be presenting at the Jefferies Radiopharma Innovation Summit, with CEO Chandler Robinson scheduled to speak. The event is set to take place in New York City and emphasizes Monopar's commitment to developing therapeutics aimed at improving the lives of cancer patients. The company has a promising pipeline, which includes treatments for various cancer types.
Read more →MNPRMonopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
Monopar Therapeutics announced that its interim analysis of the Phase 2b/3 VOICE trial for Validive, intended for the prevention of severe oral mucositis, showed it did not meet the efficacy threshold of a 15% absolute difference compared to placebo. Consequently, the company will discontinue the study and halt Validive's active development. However, Monopar stated it has adequate funding to support its other ongoing projects beyond the first quarter of 2024. The findings were communicated by an independent Data Safety Monitoring Board, which confirmed no safety concerns with Validive.
Read more →MNPRMonopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments Validive Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next Week Camsirubicin Phase 1b Dose
Monopar Therapeutics has reported its fourth-quarter and full-year financial results for 2022, alongside significant developments in its clinical trials. The Validive Phase 2b/3 trial is on track for a Go/No-Go interim analysis expected by the end of next week. Meanwhile, the Camsirubicin Phase 1b trial is enrolling patients in a fifth dose-level cohort, showing improved median progression-free survival compared to previous studies. Additionally, preclinical studies suggest promising results for their antibody MNPR-101 and its analog MNPR-202 in cancer treatment.
Read more →MNPRMonopar to Present at the 35th Annual Roth Conference
Monopar Therapeutics Inc. will have its CEO Chandler Robinson speak at the 35th Annual Roth Conference on March 13, 2023. The event will take place at The Ritz Carlton in Laguna Niguel, California. Monopar is focused on developing therapeutics intended to extend life or improve quality of life for cancer patients, with a diverse pipeline that includes both early-stage and later-stage candidates.
Read more →MNPRMonopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials WILMETTE, Ill. And
Monopar Therapeutics Inc. and NorthStar Medical Radioisotopes have announced an expansion of their collaboration in radiopharmaceuticals, highlighted by positive preclinical results for a new imaging candidate MNPR-101-Zr. This zirconium-89 labeled version showed substantial tumor uptake in multiple cancer types, paving the way for a planned first-in-human study. The companies are committed to further funding to advance this program. The findings suggest MNPR-101 could be a valuable tool for both imaging and treatment in oncology.
Read more →MNPRMonopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
Monopar Therapeutics has provided an update on its Phase 1b trial for camsirubicin, a novel treatment for advanced soft tissue sarcoma. The trial has started enrolling patients at a higher dose, demonstrating a promising side effect profile, with no observed cardiotoxicity and lower instances of hair loss and oral mucositis compared to standard treatment doxorubicin. Notably, Monopar is increasing its clinical trial sites to enhance recruitment efforts. This update may signal potential advancements in therapy options for patients with significant unmet medical needs in this area.
Read more →MNPRMonopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101
Monopar Therapeutics Inc. has announced a timeline for reporting key data events in Q1 2023, including interim analyses for its Validive Phase 2b/3 trial and updates from its camsirubicin Phase 1b trial. The company will also provide insights on MNPR-101 RIT preclinical data. While the news is largely positive, the company faces challenges such as potential delays in data reporting and risk factors related to patient recruitment and trial outcomes. The interim analysis for Validive is expected to be done by March 2023.
Read more →MNPRMonopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m 2
Monopar Therapeutics has announced the advancement of its camsirubicin Phase 1b clinical trial to the fifth dose level of 650 mg/m2 following positive recommendations from the safety review committee. This milestone is significant as it allows for increased potential anti-tumor activity, given that higher doses of this class of drugs are known to be effective. Early results from the trial show a favorable safety profile compared to doxorubicin and an improvement in median progression-free survival over a prior trial. The trial aims to study the drug's effects while using prophylactic G-CSF to manage adverse effects.
Read more →MNPR▼ -19%on this news
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
mnpr_ex991.htm EXHIBIT 99.1 Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration WILMETTE, Ill, December 12, 2022 - Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing propr
Read more →MNPRMonopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
mnpr_ex991.htm EXHIBIT 99.1 Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial WILMETTE, Ill, November 16, 2022 - Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeuti
Read more →MNPR▼ -24.8%on this news· ran to -36% by day 3
Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments Validive Phase 2b/3 Interim Analysis on Track for Q1 2023 Camsirubicin Clinical Data at CTOS 2022 Next Week MNPR-202 Precl
mnpr_ex991.htm EXHIBIT 99.1 Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments Validive Phase 2b/3 Interim Analysis on Track for Q1 2023 Camsirubicin Clinical Data at CTOS 2022 Next Week MNPR-202 Preclinical Data at ASH 2022 in
Read more →MNPRMonopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will be presenting cli
Read more →MNPRMonopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
WILMETTE, Ill., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that t
Read more →MNPRMonopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that i
Read more →MNPRMonopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis Interim Analysis Planned for Q1 2023
wordproof.doc EXHIBIT 99.1 Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis Interim Analysis Planned for Q1 2023 WILMETTE, Ill, October 5, 2022 - Monopar Therapeutics Inc. (Nasdaq: MNPR),
Read more →MNPRMonopar to Present at Roth Inaugural Healthcare Opportunities Conference
WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that
Read more →MNPRMonopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments Validive Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analy
mnpr_ex991.htm EXHIBIT 99.1 Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments Validive Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analysis Anticipated in Q1 2023 C
Read more →MNPR▼ -8%on this news
Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments Validive Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward Interim Camsirubicin Phase 1b Dose-Escalation Trial Cl
mnpr_ex991.htm EXHIBIT 99.1 Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments Validive Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward Interim Camsirubicin Phase 1b Dose-Escalation Trial Clears 3rd Dose Level, Now Enr
Read more →MNPRMonopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments Validive Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments Validive Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe Camsirubicin Phase 1b Dose-Esclation Trial Clears 2nd Dose Level and is Now Enrolling
Read more →MNPRMonopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe Camsirubicin Phase 1b Dose-Esclation Trial Clears 2nd Dose Level and is Now Enrolling 3rd Dose-Level Cohort WILMETTE, Ill., March 24, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or th
Read more →MNPR▼ -6%on this news
Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference
WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that
Read more →MNPR▲ +6.2%on this news
Monopar Announces Clinical and Preclinical Program Updates - Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU - Open-label Phase 1b camsirubicin trial: early signs of clinical benef
mnpr_ex991.htm EXHIBIT 99.1 Monopar Announces Clinical and Preclinical Program Updates - Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU - Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed WILMETTE, Ill, F
Read more →MNPR▲ +6.7%on this news
Monopar to Present at the H.C. Wainwright BioConnect Conference
WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that C
Read more →MNPRMonopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial
Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial WILMETTE, Ill, December 8, 2021 Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to e
Read more →MNPRMonopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S. Validive Phase 2b/3 VOICE Trial Cleared to Enroll in
mnpr_ex991.htm EXHIBIT 99.1 Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S. Validive Phase 2b/3 VOICE Trial Cleared to Enroll in Europe and on Track for Re
Read more →MNPR▲ +8.3%on this news
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
mnpr_ex991.htm EXHIBIT 99.1 Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma WILMETTE, Ill, October 27, 2021 - Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company
Read more →MNPRMonopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma
mnpr_ex991.htm EXHIBIT 99.1 Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma WILMETTE, Ill, September 16, 2021 - Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focus
Read more →MNPR▼ -7.6%on this newsshared move
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe - Trial launch in Europe coincides with the Company's upcoming presentation at the European Society for Medical Oncology Congress
PRESS RELEASE DATED SEPTEMBER 13, 2021 mnpr_ex991.htm EXHIBIT 99.1 Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe WILMETTE, Ill., September 13, 2021 - Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing propriet
Read more →MNPR▲ +9.9%on this newsshared move
Monopar Therapeutics to Present at Upcoming Investor Conferences in September
WILMETTE, Ill., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today annou
Read more →MNPRMonopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates Camsirubicin Phase 1b Clinical Trial Anticipated to Start in the U.S. in Q4 2021 Validive ® Phase 2b/3 VOICE Trial on Tr
Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates Camsirubicin Phase 1b Clinical Trial Anticipated to Start in the Phase 2b/3 VOICE Trial on Track for Reaching Interim Analysis in H1 2022 IL, August 12, 2021 Monopar Therapeutics I
Read more →MNPRMonopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive ® VOICE Trial
Monopar Reaches Target Number of Clinical Sites Portion of 2b/3 Validive WILMETTE, Ill., August 5, 2021 Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or im
Read more →MNPRMonopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma
Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma WILMETTE, Ill., August 3, 2021 Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary
Read more →MNPRMonopar Appoints Octávio Costa, MD, as Chief Medical Officer
Monopar Appoints Oct vio Costa, MD, as Chief Medical Ill., July 12, 2021 Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for c
Read more →MNPRMonopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive ® Trial at MASCC/ISOO
Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive Trial at 24, 2021 Monopar Therapeutics Inc. (Nasdaq: MNPR) a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to
Read more →MNPRMonopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer
WILMETTE, Ill., June 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announ
Read more →MNPRMonopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic
WILMETTE, Ill. and BELOIT, Wis., May 26, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional composition of matter patent titled “Urokinase Plasminogen Activator Receptor-Targeted
Read more →MNPRMonopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery
WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled “Bio-Targeted Radiophar
Read more →MNPRMonopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
First Patient Dosed in Validive® Phase 2b/3 VOICE Clinical Trial Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021 Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Surgery WILMETTE, Ill., May 13, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics
Read more →MNPRMonopar’s uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study
WILMETTE, Ill., March 30, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today annou
Read more →MNPRMonopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates
Validive® Phase 2b/3 VOICE Clinical Trial Commenced Camsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021 MNPR-101-Conjugate Data Published in European Journal of Cancer WILMETTE, Ill., March 25, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the
Read more →MNPRMonopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery
WILMETTE, Ill., March 02, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today annou
Read more →MNPRMonopar Therapeutics to Present at Upcoming Investor Conferences
WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announ
Read more →MNPRMonopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations
WILMETTE, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announ
Read more →MNPRMonopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
WILMETTE, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announ
Read more →MNPRMonopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announ
Read more →MNPRMonopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada
WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life and improve the quality of life for cancer patients, today annou
Read more →MNPRMonopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs
-Issued patent expands and strengthens Monopar’s existing camsirubicin IP portfolio -Phase 2 initiation for camsirubicin in advanced soft tissue sarcoma remains on track for early 2021 WILMETTE, Ill., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a
Read more →MNPRMonopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase plasminogen activator receptor targeted radio-immuno-therapeutic (uPRIT) for the potentia
Read more →MNPRMonopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM WILMETTE, Ill., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeu
Read more →MNPRMonopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
Validive® Phase 2b/3 Clinical Trial on Track to Start Before Year-end Issuance of New Patents For Validive Camsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021 WILMETTE, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Na
Read more →MNPRMonopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive
WILMETTE, Ill., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announ
Read more →MNPRMonopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020
WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at the H.C. Wainwright 22nd Annual Global Investment Conference, Healthcare & Biotec
Read more →MNPRMonopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing urokinase plasminogen activator receptor targeted radio-immuno-therapeutics (uPRITs) f
Read more →MNPRMonopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19
WILMETTE, Ill. and BELOIT, Wis. and MORGAN HILL, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), who are collaborating on the development of urokinase plasminogen activator re
Read more →MNPRMonopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
WILMETTE, Ill., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus unlikely to progress to severe respiratory failure. The test would use Monopar’s
Read more →MNPRMonopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), who are collaborating on the development of Radio-Immuno-Therapeutics (RITs) to tr
Read more →MNPRMonopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates
CHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer pati
Read more →MNPRMonopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR
CHICAGO and BELOIT, Wis., June 30, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today that a provisional patent application entitled “Precision Radioimmunotherapeutic Targeting of t
Read more →MNPRMonopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19
CHICAGO and BELOIT, Wis., June 16, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today a 50/50 collaboration to develop potential Radio-Immuno-Therapeutics (RITs) to treat severe COV
Read more →MNPRMonopar Therapeutics Reports First Quarter 2020 Financial Results and Business Updates
CHICAGO, May 07, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today
Read more →MNPRMonopar Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Business Updates
Initial public offering on Nasdaq Capital Market in December 2019 Orphan Drug Designation from the European Commission for camsirubicin for the treatment of soft tissue sarcoma CHICAGO, March 27, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasda
Read more →MNPRADDITIONAL EXHIBITS exh99-1q42019earningsrele Monopar Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Business Updates Initial public offering on Nasdaq Capital Market in December 2019 Orphan
Monopar Therapeutics Reports Fourth Quarter and Full-Year Financial Results and Business Updates Initial public offering on Nasdaq Capital Market in December Orphan Drug Designation from the European Commission camsirubicin for the treatment of soft tissue sarcoma IL, March
Read more →MNPRMonopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma
CHICAGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ: MNPR) today announced it has been granted Orphan Drug Designation from the European Commission for its drug candidate camsirubicin in the treatment of soft tissue sarcoma (STS), and the European Medicin
Read more →MNPRMonopar Therapeutics Inc. Announces Closing of Initial Public Offering of Common Stock
CHICAGO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced the closing of its initial public offering of 1,277,778 shares of common stock, including the underwriters’ exercise of its over-allotment option, at a public offering price of $8.00 per share be
Read more →MNPRMonopar Therapeutics Inc. Announces Full Exercise of Over-Allotment by Underwriters
CHICAGO, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced that the underwriters of its previously announced initial public offering of common stock have exercised in full their option to purchase an additional 166,666 shares of common stock. The additio
Read more →MNPRMonopar Therapeutics Inc. Announces Pricing of Initial Public Offering
CHICAGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced that it has priced an initial public offering of 1,111,112 shares of its common stock at $8.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market on December 19, 201
Read more →Competitive Position
How MNPR ranks across every disease it competes inCompetitive Position is a premium feature
See how MNPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial